- Special thanks
-
Kim SU
- KMID: 2539785
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S4-S4.
- doi: 10.3350/cmh.2023.0010
-
- CITED
-
- Close
- SHARE
-
- Close
- Preface
-
Kim SU
- KMID: 2539784
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S3-S3.
- doi: 10.3350/cmh.2023.0014
-
- CITED
-
- Close
- SHARE
-
- Close
- Preface
-
Kim YJ
- KMID: 2539783
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S2-S2.
- doi: 10.3350/cmh.2023.0011
-
- CITED
-
- Close
- SHARE
-
- Close
- Congratulatory remarks
-
Bae SH
- KMID: 2539782
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S1-S1.
- doi: 10.3350/cmh.2023.0027
-
- CITED
-
- Close
- SHARE
-
- Close
- Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management
-
Geerts A, Lefere S
- KMID: 2539808
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S276-S285.
- doi: 10.3350/cmh.2022.0373
The prevalence of obesity and metabolic consequences such as nonalcoholic fatty liver diseases (NAFLD) has become a crucial health problem. Lifestyle modifications, especially weight loss, effectively reduces liver injury in... -
- CITED
-
- Close
- SHARE
-
- Close
- The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
-
Oh H, Sohn W, Cho YK
- KMID: 2539806
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S261-S267.
- doi: 10.3350/cmh.2022.0393
Non-alcoholic fatty liver disease (NAFLD) is accepted as a counterpart to alcohol-related liver disease because it is defined as hepatic steatosis without excessive use of alcohol. However, the definition of... -
- CITED
-
- Close
- SHARE
-
- Close
- MAFLD: How is it different from NAFLD?
-
Gofton C, Upendran Y, Zheng MH, George J
- KMID: 2539787
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S17-S31.
- doi: 10.3350/cmh.2022.0367
“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
-
An J, Sohn JH
- KMID: 2539807
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S268-S275.
- doi: 10.3350/cmh.2022.0437
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD, is characterized... -
- CITED
-
- Close
- SHARE
-
- Close
- Interaction between sarcopenia and nonalcoholic fatty liver disease
-
Joo SK, Kim W
- KMID: 2539791
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S68-S78.
- doi: 10.3350/cmh.2022.0358
Sarcopenia and nonalcoholic fatty liver disease (NAFLD) are common health problems related to aging. Despite the differences in their diagnostic methods, several cross-sectional and longitudinal studies have revealed the close... -
- CITED
-
- Close
- SHARE
-
- Close
- Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
-
Sookoian S, Pirola CJ
- KMID: 2539800
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S184-S195.
- doi: 10.3350/cmh.2022.0318
The knowledge on the genetic component of non-alcoholic fatty liver disease (NAFLD) has grown exponentially over the last 10 to 15 years. This review summarizes the current evidence and the... -
- CITED
-
- Close
- SHARE
-
- Close
- Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
-
Ahn SB
- KMID: 2539797
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S150-S156.
- doi: 10.3350/cmh.2022.0362
Nonalcoholic fatty liver disease (NAFLD) affects approximately 30% of the population worldwide and includes nonalcoholic fatty liver, nonalcoholic steatohepatitis (NASH), and cirrhosis. Since NAFLD-associated diseases begin with steatosis, the early... -
- CITED
-
- Close
- SHARE
-
- Close
- Global incidence and prevalence of nonalcoholic fatty liver disease
-
Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, Yang JD, Tan E, Muthiah MD
- KMID: 2539788
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S32-S42.
- doi: 10.3350/cmh.2022.0365
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease worldwide. The estimated global incidence of NAFLD is 47 cases per 1,000 population and is higher among males... -
- CITED
-
- Close
- SHARE
-
- Close
- Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
-
Nogami A, Yoneda M, Iwaki M, Kobayashi T, Honda Y, Ogawa Y, Imajo K, Saito S, Nakajima A
- KMID: 2539795
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S123-S135.
- doi: 10.3350/cmh.2022.0357
Non-alcoholic fatty liver disease is currently the most common chronic liver disease, affecting up to 25% of the global population. Simple fatty liver, in which fat is deposited in the... -
- CITED
-
- Close
- SHARE
-
- Close
- Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma
-
Cho Y, Kim BH, Park JW
- KMID: 2539803
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S220-S227.
- doi: 10.3350/cmh.2022.0360
The incidence of hepatocellular carcinoma (HCC) associated with nonalcoholic fatty liver disease (NAFLD) has been increasing worldwide, including Asia. Most patients with NAFLD-related HCC are at a much-advanced stage and... -
- CITED
-
- Close
- SHARE
-
- Close
- Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
-
Konyn P, Ahmed A, Kim D
- KMID: 2539789
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S43-S57.
- doi: 10.3350/cmh.2022.0351
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States and worldwide. Though nonalcoholic fatty liver per se may not be independently... -
- CITED
-
- Close
- SHARE
-
- Close
- Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
-
Semmler G, Datz C, Trauner M
- KMID: 2539805
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S244-S260.
- doi: 10.3350/cmh.2022.0364
Nutrition and dietary interventions are a central component in the pathophysiology, but also a cornerstone in the management of patients with non-alcoholic fatty liver disease (NAFLD). Summarizing our rapidly advancing... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison between obese and non-obese nonalcoholic fatty liver disease
-
Chan WK
- KMID: 2539790
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S58-S67.
- doi: 10.3350/cmh.2022.0350
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions that are characterized by excess accumulation of fat in the liver, and is diagnosed after exclusion of significant alcohol... -
- CITED
-
- Close
- SHARE
-
- Close
- Nonalcoholic fatty liver disease and non-liver comorbidities
-
Manikat R, Nguyen MH
- KMID: 2539793
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):s86-s102.
- doi: 10.3350/cmh.2022.0442
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by excess fat accumulation in the liver. It is closely associated with metabolic syndrome, and patients with NAFLD often... -
- CITED
-
- Close
- SHARE
-
- Close
- Non-alcoholic fatty liver disease: Definition and subtypes
-
Han SK, Baik SK, Kim MY
- KMID: 2539786
- Clin Mol Hepatol.
- 2023 Feb;29(suppl):S5-S16.
- doi: 10.3350/cmh.2022.0424
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide, with a global prevalence of approximately 30%. However, the prevalence of NAFLD has been variously reported... -
- CITED
-
- Close
- SHARE
-
- Close
- Screening strategy for non-alcoholic fatty liver disease
-
Zhang S, Mak LY, Yuen MF, Seto WK
- KMID: 2539794
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S103-S122.
- doi: 10.3350/cmh.2022.0336
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting approximately 25% of the general population worldwide, and is forecasted to increase global health burden in the... -
- CITED
-
- Close
- SHARE
-
- Close
